Literature DB >> 2584251

Methotrexate diffusion from acrylic cement. Local chemotherapy for bone tumours.

P Hernigou1, J P Thiéry, J Benoit, M C Voisin, P Leroux, G Hagege, G Delepine, D Goutallier.   

Abstract

We investigated the possible use of acrylic cement containing chemotherapeutic drugs in the treatment of malignant lesions in bone. The diffusion of methotrexate (MTX) from methylpolymethacrylate implants was studied in vitro: polymerisation of the cement did not destroy the drug; liberation began immediately and about 10% was released by 18 hours. Some release continued for as long as six months. In vivo experiments on rats with induced osteosarcoma showed that MTX in cement had both local and general effects which were dependent on the dosage. A series of 17 large dogs with spontaneous osteosarcoma were then treated by local resection and cement containing MTX. General chemotherapeutic effects were detectable from 2 hours to 5 days, survival was increased and local recurrence was reduced, but there were four cases of delayed wound healing. Preliminary studies in human patients confirm the possibility that this method of local chemotherapy could be a useful addition to the treatment of malignant tumours of bone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584251

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  15 in total

1.  Cadmium in bone cement induces necrosis and decreases the viability of residual osteosarcoma cells: A xenograft study.

Authors:  Nihat Demirhan Demirkıran; Safiye Aktaş; Ayşe Pınar Erçetin Özdemir; Ömer Bekçioğlu; Melek Aydın; Hasan Havitçioğlu
Journal:  Acta Orthop Traumatol Turc       Date:  2020-07       Impact factor: 1.511

Review 2.  The unusual routes of administration.

Authors:  E Beyssac
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

3.  Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs.

Authors:  Rafael Llombart-Blanco; Carlos Villas; Álvaro Silva; Azucena Aldaz; Iñigo Navarro; Jeronimo Forteza; Salvador Martin Algarra; Matías Alfonso
Journal:  Eur Spine J       Date:  2017-02-06       Impact factor: 3.134

4.  The use of fluoride cement: preliminary experimental study and clinical application.

Authors:  Claudia Di Bella; Enrico Lucarelli; Milena Fini; Roberto Giardino; Mario Mercuri; Davide Donati
Journal:  Chir Organi Mov       Date:  2008-05-21

5.  Methotrexate released in vitro from bone cement inhibits human stem cell proliferation in S/G2 phase.

Authors:  Egon Prochazka; Tomas Soukup; Milos Hroch; Leos Fuksa; Eva Brcakova; Jolana Cermanova; Gabriela Kolouchova; Karel Urban; Jaroslav Mokry; Stanislav Micuda
Journal:  Int Orthop       Date:  2009-02-11       Impact factor: 3.075

6.  Local control after surgical treatment of spinal metastatic disease.

Authors:  G Missenard; P Lapresle; D Cote
Journal:  Eur Spine J       Date:  1996       Impact factor: 3.134

7.  Perioperative management of medications used in the treatment of rheumatoid arthritis.

Authors:  Carla R Scanzello; Mark P Figgie; Bryan J Nestor; Susan M Goodman
Journal:  HSS J       Date:  2006-09

8.  Methotrexate-added acrylic cement: biological and physical properties.

Authors:  G Maccauro; A Cittadini; M Casarci; F Muratori; D De Angelis; C Piconi; M A Rosa; A Spadoni; M Braden; A Sgambato
Journal:  J Mater Sci Mater Med       Date:  2007-01-04       Impact factor: 4.727

9.  Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration.

Authors:  Anas Nooh; Yu Ling Zhang; Daisuke Sato; Derek H Rosenzweig; Sébastien Tabariès; Peter Siegel; Jake E Barralet; Michael H Weber
Journal:  J Bone Oncol       Date:  2017-01-13       Impact factor: 4.072

10.  Effects of Incorporating Carboxymethyl Chitosan into PMMA Bone Cement Containing Methotrexate.

Authors:  Bo-Ming Liu; Ming Li; Bao-Sheng Yin; Ji-Yang Zou; Wei-Guo Zhang; Shou-Yu Wang
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.